Founded in 2016 from pioneering ‘muco-trapping’ antibody research at Johns Hopkins and UNC Chapel Hill, Mucommune is an integrated biotechnology company that is now advancing innovations in immunoengineering, drug and gene delivery, and mucosal therapeutics. In early 2019, Mucommune spun off Inhalon Biopharma to commercialize its pipeline of inhaled immunotherapies for acute respiratory infections. Since then, Inhalon has raised over $50M, became a clinical-stage company, and is actively advancing a rich pipeline of four potentially first-in-class products.

 

Mucommune’s consistent success in transforming early bench discoveries into clinical stage assets has shaped its evolution into a unique specialized R&D enterprise dedicated to bridging the gap between academic innovation and clinical translation.

 

Currently, Mucommune’s R&D portfolio encompasses three technology platforms spanning the areas of female reproductive health (codenamed “Elleon”), polymer immunogenicity (codenamed “Polyon”), and in vivo engineering of immune cells.

Mucommune is located in Discovery II at Perimeter Park in the Research Triangle.